Taylor Ben R, an insider at Recursion Pharmaceuticals Inc (RXRX), sold 782,933 shares of the company's stock on December 14, 2025, at a price of $4.33 per share, totaling $3.39 million. Following this transaction, Ben retains 782,933 shares of Recursion.
This sale highlights a significant transaction by an insider in the biotechnology firm, which focuses on discovering novel medicines through automation and artificial intelligence. Recursion, headquartered in Salt Lake City, Utah, has a market cap of $2.4 billion and reported a trailing twelve-month EPS of -1.81.
Insider sales can arise from various motivations, including diversification and personal financial needs. While noteworthy, such transactions do not inherently indicate a negative outlook on the company. Investors are encouraged to consider insider activity in the context of broader market trends and other fundamental factors.
Recursion Pharmaceuticals is set to report its next earnings on May 4, 2026, with an estimated EPS of -0.36 and revenue of $16.6 million. The company's clinical programs include REC-617, a CDK7 inhibitor for advanced solid tumors, among others.
Insider transactions are reported to the SEC, providing transparency into executive stock movements. However, isolated sales should not solely guide investment decisions; examining patterns across multiple insiders offers a more comprehensive view.